Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — 8th Annual SVB Leerink Global Healthcare Conference (February 2019)
11 slides from Ironwood Pharmaceuticals's conference presentation, Feb 28, 2019
Slide 1: Leerink Healthcare Conference
A COMMERCIAL BIOTECHNOLOGY COMPANY Leerink Healthcare Conference February 28, 2019
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about expectations and timing regarding Ironwood’s ability to achieve profitability; the development, launch
Slide 3: New Ironwood and Cyclerion: pivotal moment to grow two industry-leading companies
New Ironwood and Cyclerion: pivotal moment to grow two industry-leading companies and unlock shareholder value Ironwood Today expected to: LINZESS / CONSTELLA Build a leading GI franchise GI IW-3718 Accelerate growth of LINZESS® and advance GI development programs MD-7246 Deliver profits begin
Slide 4: Separation: on track to launch early April 2019
Separation: on track to launch early April 2019 • Mark Mallon to be Ironwood CEO effective upon separation • Peter Hecht to be Cyclerion CEO Right leadership, right time • Experienced leadership teams complemented with new skills • Two diverse, experienced and non-overlapping boards (Julie McHugh ex
Slide 5: Ironwood is building a profitable, GI-focused healthcare company
WE AIM TO: Grow LINZESS® (linaclotide) and accelerate U.S. GI development portfolio Capitalize on our GI expertise to IRONWOOD bring innovative therapies to patients is building a profitable, GI-focused healthcare company Deliver profits beginning in 20191 (following planned separation) 1. Profitabi
Slide 6: Capitalizing on our expertise in GI to bring innovative therapies to patients
Capitalizing on our expertise in GI to bring innovative therapies to patients Accelerate LINZESS Advance late-stage Invest in growth & value growth and profitability1 development programs creation Linaclotide abdominal symptom Ironwood is seeking to: claims (bloating, discomfort, pain) 2,900,000 2,8
Slide 7: 2019 Financial Guidance
2019 Financial Guidance Ironwood expects Total revenue $370 – 390 million Net interest expense ~$35 million Separation expenses1 $30 – 40 million Restructuring expenses $3 – 4 million Ironwood expects to provide guidance on 2019 non-GAAP profitability from continuing operations at an investor update
Slide 8: Cyclerion: Creating breakthrough treatments for serious & orphan diseases
Cyclerion: Creating breakthrough treatments for patients with serious & orphan diseases by harnessing the power of sGC 5 Differentiated programs 4 Clinical studies ongoing 3 Phase 2 readouts expected 2 New tissue-tailored development candidates 1 1 Great company launch 1. Expect to nominate 2 candid
Slide 9: 4 clinical data readouts in 2019 on differentiated compounds
4 clinical data readouts in 2019 on differentiated compounds Product* Discovery IND Enabling Phase 1 Phase 2 Phase 3 Status and Anticipated Next Milestones Vascular sGC Stimulator - Top line data expected in 2H2019 Olinciguat Sickle Cell Disease - Granted Orphan Drug Designation by the US FDA - Worl
Slide 10: A Commercial Biotechnology Company
A COMMERCIAL BIOTECHNOLOGY COMPANY
Slide 11: 4Q and Full Year 2018 Financial Summary
4Q and Full Year 2018 Financial Summary LINZESS U.S. Brand Collaboration Ironwood Revenue/Expense Calculation Ironwood & Allergan Combined U.S. LINZESS P&L Commercial Pool1 Year Ended Three Months Ended Year Ended December 31, 2018 December 31, 2018 December 31, 2018 (000s) (000s) (000s) Three Month